Peng Ying, Wei Qinglin, He Yonghong, Xie Qiaoling, Liang Yanchao, Zhang Liangjun, Xia Yiju, Li Yan, Chen Wensheng, Zhao Jingjing, Chai Jin
Cholestatic Liver Diseases Center and Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University) , Chongqing, China.
Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University) , Chongqing, China.
Expert Rev Gastroenterol Hepatol. 2020 May;14(5):383-400. doi: 10.1080/17474124.2020.1748010. Epub 2020 May 20.
Hepatocellular carcinoma (HCC) is an aggressive tumor type which results in poor prognosis. ALBI and Child-Pugh score have been widely applied for predicting prognosis in patients with liver diseases. We conducted a systematic review to compare the prognostic ability of ALBI versus Child-Pugh in HCC patients.
PubMed, EMBASE and Cochrane Library were explored. The data were extracted from every study. Studies investigating HCC patients and comparing the predicting ability between ALBI and Child-Pugh were analyzed.
This systematic review revealed that ALBI showed better discriminative ability than Child-Pugh for predicting the prognosis in HCC patients. However, the predictive abilities of two scores should be improved. Except for the most common used serum biomarker AFP for diagnosis and surveillance of HCC, recent studies have also explored all aspects of HCC through genome-wide sequencing, exome sequencing, RNA sequencing and genome-wide methylation analysis which provide essential clues for genotyping of HCC. Further studies should explore biomarkers by advanced techniques to validate new prognostic tools for early diagnosis and prognosis of HCC. Moreover, multicenter prospective studies should be carried out to compare the prognostic values of predictive indicators in HCC population in the future.
肝细胞癌(HCC)是一种侵袭性肿瘤类型,预后较差。ALBI和Child-Pugh评分已广泛应用于预测肝病患者的预后。我们进行了一项系统评价,以比较ALBI与Child-Pugh在肝癌患者中的预后预测能力。
检索了PubMed、EMBASE和Cochrane图书馆。从每项研究中提取数据。分析了调查肝癌患者并比较ALBI和Child-Pugh预测能力的研究。
该系统评价显示,在预测肝癌患者预后方面,ALBI的鉴别能力优于Child-Pugh。然而,两种评分的预测能力都有待提高。除了最常用的血清生物标志物甲胎蛋白用于肝癌的诊断和监测外,最近的研究还通过全基因组测序、外显子组测序、RNA测序和全基因组甲基化分析等对肝癌的各个方面进行了探索,这些为肝癌的基因分型提供了重要线索。未来的进一步研究应通过先进技术探索生物标志物,以验证用于肝癌早期诊断和预后的新预后工具。此外,未来应开展多中心前瞻性研究,比较预测指标在肝癌人群中的预后价值。